Tratamiento de la hipertensión arterial

Panza, 1997, Endothelial dysfunction in essential hypertension, Clin Cardiol, 26 Rao, 2001, Insulin resistance syndrome, Am Fam Physician, 63, 1159 Ruilope, 2001, Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use, Hypertension, 38, 537, 10.1161/hy09t1.095760 1997, Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention. Phase II, Arch Intern Med, 157, 657, 10.1001/archinte.1997.00440270105009 Mediavilla, 1997, Importancia del índice de masa corporal en una Unidad de HTA, Hipertensión, 14, 113 Moore, 1999, Effect of dietary patterns on ambulatory blood pressure. Results from the Dietary Approaches to Stop Hypertension (DASH) trial, Hypertension, 34, 472, 10.1161/01.HYP.34.3.472 Lahoz, 1999, Las dietas enriquecidas en ácidos grasos monoinsaturados y ácidos grasos poliinsaturados omega 3 disminuyen la presión arterial, sin modificar la concentración de insulina plasmática en sujetos sanos, Med Clin (Barc), 112, 133 DeSouza, 2000, Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men, Circulation, 102, 1351, 10.1161/01.CIR.102.12.1351 Whelton, 1998, For TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the Elderly (TONE), JAMA, 279, 839, 10.1001/jama.279.11.839 Fuchs, 2001, Alcohol consumption and the incidence of hypertension. The Atherosclerosis Risk in Communities Study, Hypertension, 37, 1242, 10.1161/01.HYP.37.5.1242 1997, The Sixth Report of the Joint National Committee on Prevention, Detection and Treatment of High Blood Pressure (JNC-VI), Arch Intern Med, 157, 2413, 10.1001/archinte.1997.00440420033005 1999, 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension, J Hypertens, 17, 151 Neaton, 1993, Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group, JAMA, 270, 713, 10.1001/jama.1993.03510060059034 Materson, 1993, Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Departament of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, N Engl J Med, 328, 914, 10.1056/NEJM199304013281303 Curb, 1996, Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hipertensión. Systolic Hypertension in the Elderly Program Cooperative Research Group, JAMA, 276, 1886, 10.1001/jama.1996.03540230036032 1991, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP), JAMA, 265, 3255, 10.1001/jama.1991.03460240051027 Guez, 1996, Traitement de I'hypertension artérielle par I'indapamide 1, 5 mg comprimé enrobé á libération prolongée: synthése des résultats, Arch Mal Coeur, 89, 17 Gosse, 2000, Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study, J Hypertens, 18, 1465, 10.1097/00004872-200018100-00015 Luft, 1993, Torasemide in the treatment of arterial hypertension, J Cardiovasc Pharmacol, 22, 32, 10.1097/00005344-199322003-00005 Fortuno, 1999, Torasemide inhibits angiotesin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats, Hypertension, 34, 138, 10.1161/01.HYP.34.1.138 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Rajagopalan, 2001, Aldosterone antagonists in the treatment of hypertesion and target organ damage, Curr Hypertens Resp, 3, 240, 10.1007/s11906-001-0046-2 Tzemos, 2001, Nebivolol reverses endothelial dysfunction in essential hypertension: a randomised, double-blind, crossover study, Circulation, 104, 511, 10.1161/hc3001.094207 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 Packer, 2001, Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, 1651, 10.1056/NEJM200105313442201 Sabio, 2001, Effects of beta-blocker therapy in severe chronic heart failure, N Engl J Med, 345, 998, 10.1056/NEJM200109273451313 Kasiske, 1995, Effects of antihypertensive therapy on serum lipids, Ann Intern Med, 122, 133, 10.7326/0003-4819-122-2-199501150-00010 Psaty, 1995, The risk of myocardial infarction associated with antihypertensive drug therapies, JAMA, 274, 620, 10.1001/jama.1995.03530080036038 Furberg, 1995, Nifedipine. Dose-related increase in mortality in patients with coronary heart diasease, Circulation, 92, 1326, 10.1161/01.CIR.92.5.1326 Pahor, 1995, Longterm survival and use of antihypertensive medications in older persons, J Am Geriatr Soc, 43, 1191, 10.1111/j.1532-5415.1995.tb07393.x Pahor, 1996, Do calcium-channel blockers increase the incidence of cancer, Am J Hypertens, 9, 695, 10.1016/0895-7061(96)00186-0 Pahor, 1996, Risk of gastrointestinal haemorrhage with cacium antagonists in hypertensive persons over 67 years old, Lancet, 347, 1061, 10.1016/S0140-6736(96)90276-7 Pahor, 2000, Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomisde controlled trial, Lancet, 356, 1949, 10.1016/S0140-6736(00)03306-7 Neal, 2000, Blood Pressure Lowering Treatment Trialists Collaboration. Effect of ACE-inhibitor, calcium antagonist, and other blood pressure-lowering drug: results of prospectively designed overviews of randomised trials, Lancet, 356, 1955, 10.1016/S0140-6736(00)03307-9 Hansson, 1999, Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 Study (STOP-2), Lancet, 354, 1751, 10.1016/S0140-6736(99)10327-1 Brown, 2000, Morbidity and mortality in patients randomised to double-blind treatment with a long-action calcium-channel blocker or diuretic in the international Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT), Lancet, 356, 366, 10.1016/S0140-6736(00)02527-7 Hanson, 2000, Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study, Lancet, 356, 359, 10.1016/S0140-6736(00)02526-5 Pitt, 2000, for the PREVENT Investigators, Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation, 102, 1503 Simon, 2001, Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes, Circulation, 103, 2949, 10.1161/01.CIR.103.24.2949 Lindholm, 2001, Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial, Lancet, 358, 539, 10.1016/S0140-6736(01)05704-X Hanson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertensive: Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Coca, 2000, El bloqueo del sistema renina-angiotensina reduce la mortalidad y morbilidad cardiovascular atribuible a la hipertension arterial en prevencion primaria y secundaria. El final del camino, Med Clin (Barc), 115, 178, 10.1016/S0025-7753(00)71500-4 Dickerson, 1999, Optimisation of antihypertensive treatment by crossover rotation of four major classes, Lancet, 353, 2008, 10.1016/S0140-6736(98)07614-4 Materson, 1994, Angiotensin-converting enzyme inhibitors in hypertension, A dozen years of experience. Arch Intern Med, 154, 513, 10.1001/archinte.1994.00420050059006 Schmieder, 1996, Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized dobleblind studies, JAMA, 275, 1507, 10.1001/jama.1996.03530430051039 Rovira, 2000, Factores asociados con los cambios de la microalbuminuria durante el tratamiento antihipertensivo, Med Clin (Barc), 114, 721, 10.1016/S0025-7753(00)71414-X Gansevoort, 1995, Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of compartative trials, Nephrol Dial Transplant, 10, 1963 Yusuf, 2000, Effects of angiotensin-coverting-enzyme inhibitor, ramipril, on cardiovascular event in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 Lonn, 2001, Effect of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE), Circulation, 103, 919, 10.1161/01.CIR.103.7.919 2001, Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack, Lancet, 358, 1033, 10.1016/S0140-6736(01)06178-5 Furberg, 2001, Are all angiotensin-corverting enzyme inhibitors intechangeable, J Am Coll Cardiol, 37, 1456, 10.1016/S0735-1097(01)01161-5 Schlaifer, 1997, Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Dysfunction, Am J Cardiol, 80, 1594, 10.1016/S0002-9149(97)00750-9 Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricualr Enlargement trial, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001 1991, Effect of enalapril on survival in patientes with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 Torp-Pedersen, 1999, The effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction, Lancet, 354, 9, 10.1016/S0140-6736(98)09374-X Francis, 2001, What are «tissue ACE inhibitors»,and should they be used instead of other ACE inhibitors, Clev Clin J Med, 68, 185, 10.3949/ccjm.68.3.185 Boissel, 1995, J Hypertens, 13, 1059, 10.1097/00004872-199509000-00018 Hedner, 1999, Management of hypertension: the advent of a new angiotensin receptor angtagonist, J Hypertens, 17, 21 Stergiou, 2001, Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism, Am J Hyperntens, 14, 688, 10.1016/S0895-7061(01)01307-3 Conlin, 2001, Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes, Clin Ther, 23, 1999, 10.1016/S0149-2918(01)80152-1 Cuspide, 1998, Effects of losartan on blood pressure and left ventricular mass: a longterm study, High Blood Pressure, 7, 75 Thurmann, 1998, Influence of the angiotenin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension, Circulation, 98, 2037, 10.1161/01.CIR.98.19.2037 Kahan, 1998, Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbersartan and beta-blockade, J Am Coll Cardiol, 121, 469 Nielsen, 1997, Losartan reduces albuminuria in patients wiht essential hypertension: an enalapril controlled 3 moths study, Nephrol Dial Transplant, 12, 37 Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 Os, 1999, Effect of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-tomoderate hypertension. Doxazosin Investigators Study Group, J Cardiovasc Pharmacol, 33, 791, 10.1097/00005344-199905000-00017 Khoury, 1991, Alpha-blocker therapy of hypertension, An unfulfilled promise. JAMA, 266, 394, 10.1001/jama.1991.03470030094030 2000, Major cardiovascular events in hypertensive patientes randomized to doxazosin vs chlorthalidone, JAMA, 283, 1967, 10.1001/jama.283.15.1967 Schachter, 1998, Safety and tolerability of moxonidine in the treatment of hypertension, Drug Saf, 19, 191, 10.2165/00002018-199819030-00003 Coca, 1999, Combination therapy under investigation in large-scales trials: the INVEST study, J Cardiovasc Pharmacol, 34, 29 Hanson, 1998, Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6 Laragh, 2001, Abstract, closing summary, and table of contents for Largh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension, Am J Hypertens, 14, 1173, 10.1016/S0895-7061(01)02261-0 Cummings, 1991, The role of calcium channel blockers in the treatment of essential hypertension, Arch Intern Med, 151, 250, 10.1001/archinte.1991.00400020026007 Murphy, 2001, Fenolpam: a selective peripheral dopamine-reeptor agonist for the treatment of severe hypertension, N Engl J Med, 345, 1548, 10.1056/NEJMra010253 Burnett, 1999, Vasopeptidase inhibitors: a new concept in blood pressure mamangement, J Hypertens, 17, 17 Cases, 2000, Omaprilat: clinical pharmacology, Drugs of Today, 36, 817, 10.1358/dot.2000.36.12.606051 Krum, 1998, The effect of an endothellin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension, N Engl J Med, 338, 784, 10.1056/NEJM199803193381202 Epstein, 1992, Diabetes mellitus and hypertension, Hypertension, 19, 403, 10.1161/01.HYP.19.5.403 1993, Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications, J Hypertens, 11, 309, 10.1097/00004872-199303000-00012 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 317, 703, 10.1136/bmj.317.7160.703 2000, Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of the HOPE study and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7 Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension, N Engl J Med, 338, 645, 10.1056/NEJM199803053381003 Tatti, 1998, Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM, Diabetes Care, 21, 597, 10.2337/diacare.21.4.597 Lewis, 1993, The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 Parving, 2001, Evolving strategies for renoprotection: diabetic nephropathy, Curr Opin Nephrol Hypertens, 10, 515, 10.1097/00041552-200107000-00006 Lewis, 2001, Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropapthy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Parving, 2001, The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Eng J Med, 345, 870, 10.1056/NEJMoa011489 2002, Diabetes nephropaty, Diabetes Care, 25, S85, 10.2337/diacare.25.2007.S85 Klahr, 1994, The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease, N Engl J Med, 330, 877, 10.1056/NEJM199403313301301 Marín, 2001, A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease, J Hypertension, 19, 1871, 10.1097/00004872-200110000-00023 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Jafar, 2001, Angiotensing-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Ann Intern Med, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 Ruggenenti, 1999, Renopropective properties of ACE-inhibition in non-diabetic nephropaties with non-nephrotic proteinuria, Lancet, 354, 359, 10.1016/S0140-6736(98)10363-X De la Sierra, 2000, en representación del GEDEC (Grupo Español de Estudios Cardiovasculares). Relación entre el perfil de riesgo cardiovascular y la selección y utilización de los fármacos antihipertensivos, Med Clin (Barc), 115, 41, 10.1016/S0025-7753(00)71460-6 Vasan, 2001, Impact of high-normal blood pressure on the risk of cardiovascular disease, N Engl J Med 2, 345, 1291, 10.1056/NEJMoa003417